Want to see CH:PPGN full AI Analyst Report?
PPGN Stock Chart & Stats
CHF43.95
CHF0.05(0.11%)
At close: 4:00 PM EDT
CHF43.95
CHF0.05(0.11%)
Day’s Range― - ―
52-Week RangeCHF21.80 - CHF50.10
Previous CloseN/A
Volume526.45K
Average Volume (3M)135.30K
Market Cap
CHF1.46B
Enterprise ValueCHF1.63K
Total Cash (Recent Filing)CHF59.21M
Total Debt (Recent Filing)CHF139.52M
Price to Earnings (P/E)108.6
Beta1.15
Next Earnings
Mar 09, 2027EPS Estimate
0.57Next Dividend Ex-DateN/A
Dividend Yield0.35%
Share Statistics
EPS (TTM)0.43
Shares Outstanding33,125,000
10 Day Avg. Volume90,853
30 Day Avg. Volume135,303
Financial Highlights & Ratios
PEG Ratio-5.17
Price to Book (P/B)2.72
Price to Sales (P/S)2.36
P/FCF Ratio-30.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF44.10Price Target Upside0.35% Upside
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)0.86
Revenue Forecast (FY)CHF496.10M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthConsistent revenue expansion indicates ongoing demand for the group’s peptide and oligonucleotide CDMO services. A growing top line can support higher site utilization and deepen customer programs across development and commercial stages, providing a foundation for recovery.
Operating Cash FlowImproving operating cash flow in 2024–2025 shows that core operations are generating more cash even while reported earnings remain weak. This supports funding of day-to-day activity and development work internally, reducing reliance on external financing as the business scales.
Moderate Debt Relative To EquityDebt remains moderate relative to equity at about 0.26–0.30 in 2023–2024, while the company retains a sizable equity base. This gives PolyPeptide some financial flexibility to operate through its earnings recovery and invest in its CDMO platform.
Bears Say
Persistent Net LossesNet losses persisted through 2023–2025, and margins compressed sharply from the 2020–2021 peak. Continued losses weaken retained capital and show that revenue growth has not yet translated into durable profitability, leaving the business’s earnings recovery unfinished.
Volatile Free Cash FlowFree cash flow turned sharply negative in 2025 after being slightly positive in 2024, despite stronger operating cash flow. This volatility suggests that investment or working-capital needs can absorb internally generated cash, reducing the consistency of funds available for expansion or balance-sheet strengthening.
Rising Leverage DirectionTotal debt has risen meaningfully from 2021–2022 levels while equity declined modestly from 2022 to 2025, consistent with recent losses. The resulting leverage direction could narrow financial flexibility if profitability remains weak or investment demands stay elevated.
PolyPeptide Group AG News
PPGN FAQ
What was PolyPeptide Group AG’s price range in the past 12 months?
PolyPeptide Group AG lowest stock price was CHF21.80 and its highest was CHF50.10 in the past 12 months.
What is PolyPeptide Group AG’s market cap?
PolyPeptide Group AG’s market cap is CHF1.46B.
When is PolyPeptide Group AG’s upcoming earnings report date?
PolyPeptide Group AG’s upcoming earnings report date is Mar 09, 2027 which is in 163 days.
How were PolyPeptide Group AG’s earnings last quarter?
PolyPeptide Group AG released its earnings results on Aug 13, 2026. The company reported CHF0.252 earnings per share for the quarter, beating the consensus estimate of CHF0.065 by CHF0.187.
Is PolyPeptide Group AG overvalued?
According to Wall Street analysts PolyPeptide Group AG’s price is currently Undervalued.
Does PolyPeptide Group AG pay dividends?
PolyPeptide Group AG pays a Notavailable dividend of CHF0.3 which represents an annual dividend yield of 0.35%. See more information on PolyPeptide Group AG dividends here
What is PolyPeptide Group AG’s EPS estimate?
PolyPeptide Group AG’s EPS estimate is 0.57.
How many shares outstanding does PolyPeptide Group AG have?
PolyPeptide Group AG has 33,125,000 shares outstanding.
What happened to PolyPeptide Group AG’s price movement after its last earnings report?
PolyPeptide Group AG reported an EPS of CHF0.252 in its last earnings report, beating expectations of CHF0.065. Following the earnings report the stock price went up 0.114%.
Which hedge fund is a major shareholder of PolyPeptide Group AG?
Currently, no hedge funds are holding shares in CH:PPGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PolyPeptide Group AG
PolyPeptide Group AG operates globally as a contract development and manufacturing organization (CDMO), specializing in the production of Good Manufacturing Practice (GMP)-grade peptides. These peptides, available in both proprietary and generic forms, are vital for pharmaceutical and biotechnology companies, serving as key ingredients in approved medicines, compounds undergoing clinical development, and generic drug formulations. The company also produces custom research-grade peptides and actively develops neoantigen peptides to support personalized cancer therapies. Its manufacturing expertise extends to peptides used in commercially approved therapeutics, peptide-based generics for human and veterinary applications, and cosmetic peptides. Additionally, PolyPeptide Group AG provides regulatory affairs support services. Founded in 1952 and headquartered in Zug, Switzerland, the company is a subsidiary of Draupnir Holding B.V.
PPGN Stock 12 Month Forecast
Average Price Target
CHF44.10
▲(0.35% Upside)
Technical Analysis
Lonza Group Ltd
―
Bachem Holding AG
―
Siegfried Holding AG
―
Sandoz Group Ltd
―
Joincare Pharmaceutical Group Industry Co., Ltd. Sponsored GDR Class A RegS
―